Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

In December 2013, Prothena and Roche entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab. Roche has sole responsibility ...

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena Corporation plc (NASDAQ:PRTA), has announced plans to initiate Phase 3 ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Fintel reports that on May 27, 2025, Oppenheimer downgraded their outlook for Prothena (NasdaqGS:PRTA) from Outperform to Perform. Analyst Price Forecast Suggests 1,057.57% Upside As of May 7, 2025, ...

The U.K.-based biotech is set to enter mid-stage studies for its depression drug this year, while two other GABAA modulators ...